• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    Journal of Parkinson's disease

    Journal of Parkinson's disease

    JournalISSN 1877-7171eISSN 1877-718X中科院 医学 3区

    年发文量

    研究主题

    论文(1922)

    排序
    1Reply to Correspondence: Gastrointestinal Determinants of Levodopa Response in Parkinson's Disease: an Integrated Perspective.
    Quentin Damiens, Victor Mille,Justin Faure, Marie-Blanche Valnet-Rabier,Matthieu Bereau

    levodopa pharmacokinetic variability in Parkinson's disease, and we agree that gastrointestinal determinants of treatment response extend beyond gastric emptying. However, our review was deliberately focused on gastroparesis, while explicitly acknowledging that levodopa is absorbed in the duodenum and proximal jejunum and that gastrointestinal dysfunction in Parkinson's disease may involve more generalized transit abnormalities, small intestinal bacterial overgrowth, and gut microbiota-related mechanisms. Importantly, prolonged small bowel transit alone does not establish the direction or magnitude of its effect on levodopa bioavailability, nor does current evidence demonstrate that intestinal dysmotility is a more direct or predominant determinant than delayed gastric emptying. Rather than opposing gastric and intestinal mechanisms, we propose that gastric emptying, small bowel motility, and other pharmacokinetic, pharmacodynamic, and disease-related factors should be viewed as sequential, interdependent, and patient-specific determinants of levodopa response. Integrated studies combining gastrointestinal transit assessment, levodopa pharmacokinetics, and motor outcomes are therefore warranted.

    2026
    引用
    AI阅读
    加入学术空间
    2Plasma LBP and Scd14 Levels in Parkinson's Disease with Asian LRRK2 Risk Variants: Associations with Systemic Inflammation and Clinical Severity
    Tzi Shin Toh,Hans Xing Ding,Anis Nadhirah Khairul Anuar,Nurul Syuhada Zulhaimi,Jia Wei Hor, Yong Chiang Pang, Ing Xian Kong,Jannah Zulkefli,Yi Wen Tay,Lei Cheng Lit,Shen-Yang Lim,Ai Huey Tan

    LRRK2 is implicated in the Parkinson's disease (PD) microbiome–gut–brain axis. We compared plasma lipopolysaccharide-binding protein (LBP) and soluble CD14 (sCD14), markers of gut permeability and endotoxin exposure, in PD patients with/without LRRK2 p.G2385R and/or p.R1628P and controls, and examined their associations with systemic inflammation and clinical severity. Neither marker differed between groups. Among PD patients, LBP correlated with higher IL-6, TNF-α, and worse motor function, while sCD14 correlated with higher IL-6, CCL5, and worse constipation, with no LRRK2 risk variant-specific associations. Further prospective longitudinal studies are warranted to determine the clinical significance of these associations.

    2026
    引用
    AI阅读
    加入学术空间
    3SV2A PET Imaging in Parkinson's Disease and Atypical Parkinsonism: A Systematic Review of Neuroimaging Methodologies and Regional Findings
    Chiara Camastra,Carme Uribe, Angenelle Eve Rosal, Caitilin Chow, Mary Elizabeth Coulombe, Alex Murgoci,Andrea Quattrone,Antonio P Strafella

    Background Reduced presynaptic density, commonly referred to as synaptic loss, is an early and clinically relevant feature of parkinsonian disorders. The development of positron emission tomography (PET) radiotracers targeting synaptic vesicle glycoprotein 2A (SV2A) has enabled in vivo quantification of synaptic density. Objectives This systematic review examines neuroimaging methodologies and regional SV2A PET findings in Parkinson's disease (PD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and multiple system atrophy (MSA). Methods A systematic search of PubMed, Scopus, and Web of Science was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 2020 guidelines, including studies employing validated SV2A PET radiotracers to quantify synaptic density in parkinsonian populations. Risk of bias was assessed using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-2 tool. Substantial methodological heterogeneity precluded meta-analysis; findings were synthesized narratively. Results Fourteen studies were included. In PD, the substantia nigra was the most affected region, with striatal involvement more prominent in advanced disease (>6 years duration). In PSP and CBD, synaptic loss was widespread, exceeded grey matter atrophy, and correlated with clinical severity and cognitive decline; longitudinal PSP data showed reductions of approximately 3–4% per year in frontal and caudate regions. In MSA, infratentorial involvement (cerebellum, pons, medulla) predominated, enabling diagnostic differentiation with high accuracy (AUC up to 0.99). Conclusions SV2A PET reveals disease-specific patterns of reduced presynaptic availability, consistent with synaptic loss, across parkinsonian disorders, supporting its potential as a diagnostic and monitoring biomarker. Methodological harmonization and longitudinal multicenter studies are needed to establish clinical utility.

    2026
    引用
    AI阅读
    加入学术空间
    4Squalamine Prevents Motor and Non-Motor Symptoms in the Paraquat and Lectin Rat Model of the Body-First Subtype of Parkinson's Disease.
    Caroline C Swain, Vaibhavi V Peshattiwar, Dipesh Pokharel,Khoi Le, Isabel Kennedy, Julia Kalbus,Denise Barbut,Michael Zasloff,Thyagarajan Subramanian,Kala Venkiteswaran

    Increasing evidence supports the existence of a distinct body-first subtype of Parkinson's disease (PD), in which the initial site of pathology is in the gut. Animal models that recapitulate the body-first subtype of PD are needed. We tested the hypothesis that non-motor features of the body-first subtype of PD are recapitulated in the paraquat and lectin (P + L) rat model of PD, a model that has previously demonstrated the pathological motor progression of this subtype of PD. Then, we tested whether oral squalamine, a gastrointestinal prokinetic that has been shown to reduce formation of pathological α-synuclein, could prevent pathology, motor, and non-motor findings. Rats (n = 93) were orally gavaged for seven days with paraquat (1 mg/kg) and lectin (0.05%) in 1% sucrose solution. A subset of rats (n = 37) were given 30 days of squalamine (20 mg/kg) in their drinking water immediately following P + L treatment. Rats were tested for parkinsonian motor deficits, gastrointestinal dysmotility, sleep abnormalities, and cognitive deficits. Rats were euthanized and their brains processed for phospho-S129-α-synuclein pathology and neurodegeneration. We show that the P + L rat model recapitulates non-motor features and pathology of gastrointestinal dysmotility and sleep abnormalities seen in the body-first subtype of PD. We show that oral squalamine prevents motor deficits, gastrointestinal dysmotility, and sleep abnormalities, and diminishes phospho-S129-α-synuclein pathology and neurodegeneration in the nigrostriatal pathway. We show that the P + L rat model recapitulates many features of the body-first subtype of PD and provides pre-clinical evidence for the use of squalamine to mitigate progression in the body-first subtype of PD.

    2026
    引用
    AI阅读
    加入学术空间
    5Alpha-synuclein: the Main Actor at the First Patagonia Synuclein Workshop.
    Claudio O. Fernández Outón,Phelippe Do Carmo Gonçalves, Irina Fernández, Tiago F. Outeiro

    The accumulation of aggregated alpha-synuclein (aSyn) in the brain is one of the defining pathological features in Parkinson's Disease, Parkinson's Disease with Dementia, Lewy Body Dementia, and Multiple System Atrophy. For this reason, this group of disorders is collectively known as synucleinopathies. The identification of autosomal dominant mutations in the gene encoding aSyn (SNCA) in hereditary forms of disease further supports a central role for this protein in pathogenesis. The Synuclein Workshop was held for the first time in 2025 and is intended to be organized regularly every 2 years in countries of Latin America. The purpose of this series of workshops is to bring together leading experts in the field of synucleinopathies in a part of the world that is known for a strong tradition in the field, and to enable early career researchers to engage with and learn from other renowned experts, with the overall goal of discussing and advancing research in the field. In 2025, the Synuclein Workshop took place in Villa La Angostura, a city located in the province of Neuquén, Argentina. The meeting, entitled "The Patagonia Synuclein Workshop 2025", brought together 100 scientists studying both clinical and biomolecular aspects of synucleinopathies. The meeting covered many of the open questions in the field, in a format that promoted and encouraged open and unbiased discussions between the participants, and underscored the need for additional research that, hopefully, will lead to the development of new diagnostic tools and therapeutic strategies. Here, we provide a summary of the main topics discussed in the meeting, and highlight what is the current knowledge in the field, what we still do not know, and the future directions necessary for achieving the ultimate goal of the community: to offer better options to patients, families, and care-givers.

    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 1922 篇论文

    高被引作者

    作者引用发文
    Bastiaan R. Bloem5425127
    E. Ray Dorsey350722
    Michael S. Okun319020
    Todd B. Sherer30517
    M. Maral Mouradian25521
    Junn Eunsung25521
    Thomas Foltynie109722
    Patrik Brundin109138
    Per Borghammer106618
    Wyse Richard100114

    高产作者

    作者引用发文
    Bastiaan R. Bloem5425127
    Patrik Brundin109138
    Tanya Simuni76128
    Roger A. Barker70727
    K. Ray Chaudhuri76524
    Connie Marras77224
    Kevin McFarthing46922
    Daniel Weintraub54522
    E. Ray Dorsey350722
    Thomas Foltynie109722

    相关期刊

    Parkinsonism & Related Disorders
    Current Alzheimer research
    Amyotrophic lateral sclerosis & frontotemporal degeneration
    Nature Reviews Neurology
    Movement Disorders
    Neurodegenerative disease management
    Alzheimer's & Dementia: Translational Research & Clinical Interventions
    JOURNAL of ALZHEIMERS DISEASE REPORTS
    Alzheimers Research & Therapy
    npj Parkinsons Disease